Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Epilepsy 2Tuberous Sclerosis Complex-associated Refractory Seizures 1Tuberous Sclerosis 1Seizures 1Gliosarcoma 1Glioma 1Glioblastoma 1Drug Resistant Epilepsy 1Cognitive Dysfunction 1Chronic Pain 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Everolimus 18Sirolimus 15Cannabidiol 5radiprodil 3ganaxolone 3Vigabatrin 3Activator Appliances 3Melatonin 2exemestane 1dactolisib 1carbon-11 acetate 1Surveys and Questionnaires 1Simvastatin 1Sertraline 1Selective Serotonin Reuptake Inhibitors 1Propranolol 1Itraconazole 1Injections 1Fluid Therapy 1Doxycycline 1Curcumin 1Carbamazepine 1Calcitriol 1Aspirin 1Anticonvulsants 1Actigraphy 1Acceptance and Commitment Therapy 12-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Tuberous Sclerosis × Anticonvulsants × Clear all
NCT03356769 2020-06-09

Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex

Peking Union Medical College Hospital

Phase 2 Unknown
98 enrolled

Epilepsy, Seizures, Tuberous Sclerosis, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡